Compare Stocks: PMVP, IFRX, FATE, and UPB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.53 +0.4%	$2.55	$0.94 ▼ $3.23	$303.15M	2.54	1.24 million shs	4.19 million shs
IFRX InflaRx	$2.10 +1.7%	$2.00	$0.80 ▼ $2.95	$308M	2.52	782,921 shs	292,676 shs
PMVP PMV Pharmaceuticals	$1.50 +2.7%	$1.28	$1.02 ▼ $1.88	$80.19M	1.37	835,457 shs	1.18 million shs
UPB Upstream Bio	$5.34 +0.6%	$6.58	$5.21 ▼ $33.68	$292.48M	1.28	565,428 shs	1.00 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	+9.52%	+3.27%	+21.93%	+166.32%
IFRX InflaRx	0.00%	+0.24%	+3.71%	+16.07%	+77.54%
PMVP PMV Pharmaceuticals	0.00%	+7.14%	+15.38%	+32.74%	+20.00%
UPB Upstream Bio	0.00%	-6.81%	-22.04%	-14.56%	-66.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.53 +0.4%	$2.55	$0.94 ▼ $3.23	$303.15M	2.54	1.24 million shs	4.19 million shs
IFRX InflaRx	$2.10 +1.7%	$2.00	$0.80 ▼ $2.95	$308M	2.52	782,921 shs	292,676 shs
PMVP PMV Pharmaceuticals	$1.50 +2.7%	$1.28	$1.02 ▼ $1.88	$80.19M	1.37	835,457 shs	1.18 million shs
UPB Upstream Bio	$5.34 +0.6%	$6.58	$5.21 ▼ $33.68	$292.48M	1.28	565,428 shs	1.00 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	0.00%	+9.52%	+3.27%	+21.93%	+166.32%
IFRX InflaRx	0.00%	+0.24%	+3.71%	+16.07%	+77.54%
PMVP PMV Pharmaceuticals	0.00%	+7.14%	+15.38%	+32.74%	+20.00%
UPB Upstream Bio	0.00%	-6.81%	-22.04%	-14.56%	-66.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	133.20% Upside
IFRX InflaRx	2.67	Moderate Buy	$7.43	254.59% Upside
PMVP PMV Pharmaceuticals	2.80	Moderate Buy	$4.33	188.89% Upside
UPB Upstream Bio	2.43	Hold	$29.67	455.56% Upside

Current Analyst Ratings Breakdown

Latest PMVP, IFRX, FATE, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
9/9/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
9/2/2026	UPB Upstream Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$36.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	UPB Upstream Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/14/2026	UPB Upstream Bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$8.00 ➝ $9.00
8/12/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	45.59	N/A	N/A	$1.80 per share	1.41
IFRX InflaRx	$30K	10,291.34	N/A	N/A	$0.65 per share	3.22
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A
UPB Upstream Bio	$2.85M	102.62	N/A	N/A	$6.29 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)
UPB Upstream Bio	-$143.44M	-$2.90	N/A	N/A	N/A	-4,955.67%	-48.40%	-46.57%	11/4/2026 (Estimated)

Latest PMVP, IFRX, FATE, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/11/2026	Q2 2026	UPB Upstream Bio	-$0.7444	-$0.73	+$0.0144	-$0.73	$0.56 million	$0.77 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
IFRX InflaRx	N/A	8.22	8.22
PMVP PMV Pharmaceuticals	N/A	7.70	7.70
UPB Upstream Bio	N/A	27.99	27.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
IFRX InflaRx	42.39%
PMVP PMV Pharmaceuticals	90.20%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
IFRX InflaRx	16.30%
PMVP PMV Pharmaceuticals	10.15%
UPB Upstream Bio	16.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	161	119.82 million	114.14 million	Optionable
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
PMVP PMV Pharmaceuticals	54	53.46 million	48.03 million	Optionable
UPB Upstream Bio	75	54.77 million	45.76 million	N/A

PMVP, IFRX, FATE, and UPB Headlines

Recent News About These Companies

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts

September 19 at 4:13 AM | marketbeat.com

Hsbc Holdings PLC Sells 629,533 Shares of Upstream Bio, Inc. $UPB

September 18 at 3:43 AM | marketbeat.com

Squarepoint Ops LLC Buys 246,278 Shares of Upstream Bio, Inc. $UPB

September 15, 2026 | marketbeat.com

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

September 8, 2026 | quiverquant.comQ

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

September 8, 2026 | globenewswire.com

FY2028 EPS Estimates for Upstream Bio Decreased by Analyst

September 4, 2026 | marketbeat.com

BlackRock Inc. Purchases New Holdings in Upstream Bio, Inc. $UPB

September 3, 2026 | marketbeat.com

Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO)

September 2, 2026 | theglobeandmail.com

Upstream Bio (NASDAQ:UPB) Receives Buy Rating from HC Wainwright

September 2, 2026 | marketbeat.com

Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027

September 1, 2026 | finance.yahoo.com

Upstream Bio Outlines Phase 3 Plans for Verekitug

September 1, 2026 | tipranks.com

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

September 1, 2026 | globenewswire.com

Deutsche Bank AG Buys New Shares in Upstream Bio, Inc. $UPB

August 29, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $6.47 Million Investment in Upstream Bio, Inc. $UPB

August 25, 2026 | marketbeat.com

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Hold" by Analysts

August 25, 2026 | marketbeat.com

Upstream Bio Inc (UPB)

August 16, 2026 | investing.com

Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress

August 11, 2026 | markets.businessinsider.com

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

August 11, 2026 | zacks.com

Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?

July 14, 2026 | zacks.com

Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?

June 25, 2026 | insidermonkey.com

10 small-cap U.S. healthcare stocks with the weakest momentum grades

June 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP, IFRX, FATE, and UPB Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.53 +0.01 (+0.40%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.59 +0.06 (+2.21%)

As of 09/18/2026 07:30 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

InflaRx NASDAQ:IFRX

$2.10 +0.04 (+1.70%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$2.08 -0.01 (-0.67%)

As of 09/18/2026 07:30 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

PMV Pharmaceuticals NASDAQ:PMVP

$1.50 +0.04 (+2.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.07%)

As of 09/18/2026 07:56 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Upstream Bio NASDAQ:UPB

$5.34 +0.03 (+0.56%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.36 +0.02 (+0.28%)

As of 09/18/2026 07:30 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMVP, IFRX, FATE, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMVP, IFRX, FATE, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMVP, IFRX, FATE, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP, IFRX, FATE, and UPB Company Descriptions

Fate Therapeutics NASDAQ:FATE

InflaRx NASDAQ:IFRX

PMV Pharmaceuticals NASDAQ:PMVP

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMVP, IFRX, FATE, and UPB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMVP, IFRX, FATE, and UPB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMVP, IFRX, FATE, and UPB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP, IFRX, FATE, and UPB Company Descriptions

Fate Therapeutics NASDAQ:FATE

InflaRx NASDAQ:IFRX

PMV Pharmaceuticals NASDAQ:PMVP

Upstream Bio NASDAQ:UPB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools